Epithalamin

What is Epithalamin?

Epithalamin is a polypeptide extract prepared from the pineal glands of cattle. That single sentence already separates it from almost everything else catalogued on this site: it is not a defined molecule with a sequence, a molecular weight and a purity specification, but an extracted mixture whose exact composition is not publicly characterized. In the Russian literature it belongs to a class the Khavinson programme named "cytomedins" — low-molecular-weight polypeptide fractions pulled from specific animal tissues and given back as drugs for disorders of that same tissue. Its siblings are Thymalin (calf thymus), Cortexin (cerebral cortex) and Prostatilen (prostate). The work was done at what became the St. Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson and Vyacheslav Morozov, with the oncology arm run from the N.N. Petrov Research Institute of Oncology by Vladimir Anisimov. The reason this page exists in its own right is a confusion worth getting straight. Epitalon — also spelled Epithalon, sequence Ala-Glu-Asp-Gly or AEDG — is a single synthetic tetrapeptide. It was not isolated or purified out of epithalamin. Khavinson's own 2002 review states that Epitalon was "designed basing on the amino acid content of a pineal peptide extract Epithalamin" (PMID 12096440), and an independent 2025 Polish review repeats that it was "synthesized based on the amino acids composition of Epithalamin, a bovine pineal gland extract" (PMID 40141333). In other words: someone ran an amino-acid analysis on the extract, noted which residues were abundant, and built a short peptide from them. That is a very different provenance from "we found the active ingredient." It is worth noting that the Khavinson network's own papers do not describe the relationship consistently. The 2002 review says Epitalon was designed from the extract's amino-acid content; a 2007 antioxidant paper from the same institute calls Epitalon epithalamin's "active fragment" and calls epithalamin a preparation from bovine brain rather than pineal gland (PMID 17317455); a 2005 primate paper calls Epitalon "a synthetic analogue of the pharmacopoeia drug epithalamin" (PMID 15664732); a 2012 review says Epitalon was made "on its base" (PMID 22567846). Designed-from-composition, active fragment, and analogue are three different claims, and the group has published all three. A 2026 narrative review by clinicians at Johns Hopkins, Harvard and other US centres cuts through this by treating the two as chemically distinct substances and considering epithalamin studies only as historical context for Epitalon (PMID 42884164). Practically, this matters because the strongest-sounding human numbers in the entire Khavinson literature — the 266-person elderly cohort with reduced mortality, the Ukrainian coronary cohorts followed 12 and 15 years — were generated with epithalamin, the extract, not with the synthetic tetrapeptide that is actually sold to consumers. Marketing that attaches those numbers to a vial of AEDG is citing the wrong substance.

What Epithalamin Is Investigated For

Epithalamin has more human data behind it than almost any other Khavinson preparation, and that data is also the single most misattributed body of evidence in the consumer peptide world. Three human bodies of work carry the weight. A 266-person study of people over 60, run jointly by the St. Petersburg institute and the Institute of Gerontology in Kyiv, gave Thymalin and/or Epithalamin during the first 2 to 3 years of a 6 to 8 year follow-up and reported mortality 1.6 to 1.8-fold lower with Epithalamin, 2.0 to 2.1-fold lower with Thymalin, 2.5-fold lower with both, and 4.1-fold lower in a subgroup dosed annually for six years (PMID 14523363). A Ukrainian cohort of elderly coronary patients with accelerated cardiovascular aging received six courses of epithalamin over three years; at 12 years, deaths were 28% lower than control and cardiovascular mortality 2-fold lower (PMID 17426848), and a 15-year report on what appears to be the same 39-versus-40-patient cohort described decelerated cardiovascular aging, preserved physical endurance and a normalized melatonin rhythm (PMID 22451889). Separate work reports restored night-time melatonin in elderly people and in old rhesus monkeys (PMIDs 15452611, 17969590). The caveats are not incidental. None of these studies were blinded or placebo-controlled as far as their abstracts disclose; all were run by, or jointly with, the institute that developed and supplied the preparation; the two Ukrainian reports appear to be the same cohort reported twice at different follow-up points; and the 266-person result was itself published at least twice, in Russian in Advances in Gerontology and in English in Neuro Endocrinology Letters, with identical figures (PMIDs 12577695, 14523363). Effect sizes of this size from a two-to-three-year intervention have no parallel in any validated geriatric intervention, which is a reason for caution rather than enthusiasm. Nothing here has been reproduced by a group outside the programme, and there is no registered interventional trial of epithalamin anywhere.

History & Discovery

The epithalamin story begins before the Khavinson programme as such, in the work of Vladimir Dilman at the N.N. Petrov Research Institute of Oncology in Leningrad. Dilman's elevation model of ageing held that ageing is driven by a progressive loss of hypothalamic sensitivity to feedback signals, and he tested agents he thought might restore that sensitivity. The earliest PubMed-indexed appearance of epithalamin is a 1975 paper by Dilman and Vladimir Anisimov showing that epithalamin — alongside L-DOPA, diphenine and phenformin — restored the suppression of compensatory ovarian hypertrophy by oestrogen in old rats, an effect that had faded with age (PMID 1218271). The framing was explicitly neuroendocrine: the pineal gland as a regulator of hypothalamic set-points, and a pineal extract as a way to push those set-points back toward youth. Through the late 1970s and 1980s the preparation moved into human use across a scattered set of indications — gonadotropic function (PMID 6419222), traumatic shock, climacteric myocardiopathy, oncology — while Vladimir Khavinson and Vyacheslav Morozov built out the broader cytomedin programme at what became the St. Petersburg Institute of Bioregulation and Gerontology. Anisimov and Khavinson published twenty-year retrospectives of the oncology and gerontology work in 1993 and 1994, the latter in the Annals of the New York Academy of Sciences, which is roughly when the programme first reached a Western audience (PMIDs 7975386, 8010617). The 1998 Mechanisms of Ageing and Development lifespan paper is what gave it durable international visibility. The synthetic turn came next and is the source of the confusion this page exists to correct. Rather than fractionating the extract and identifying an active component, the group ran an amino-acid analysis and synthesized a tetrapeptide from the abundant residues: Ala-Glu-Asp-Gly, named Epitalon or Epithalon. Khavinson and Golubev described it in 2002 as "designed basing on the amino acid content" of the extract (PMID 12096440), and the independent 2025 review describes the synthesis as having happened "prior to its discovery in pineal gland polypeptide complex solution" (PMID 40141333) — that is, the peptide was built first and sought in the extract afterwards. From roughly 2000 onward the programme's publication output shifted decisively toward the defined synthetic peptides, which are cheaper to make, analytically verifiable and patentable in a way an extract is not. Epithalamin continued in Russian clinical use, and a successor polypeptide complex, Pineamin, was studied by the same group in 2017 (PMID 28849889). The extract's own literature has largely stopped growing: the great majority of epithalamin papers predate 2013.

How It Works

Epithalamin is made by extracting a mix of small proteins from cattle pineal glands. Nobody has published exactly what is in that mix. The idea behind it, from Russian researchers in the 1970s onward, was that tissue extracts carry signals that help the matching tissue in an ageing body work properly again — so a pineal extract should help an ageing pineal gland. The main reported effect is on melatonin: in older people whose night-time melatonin has dropped, a course of epithalamin is reported to bring it back up. Reports also describe antioxidant effects and longer lifespan in flies, mice and rats. Two things to hold onto. First, epithalamin is not the same thing as epitalon, the four-amino-acid peptide sold today — Russian researchers built that peptide using the amino acids they found in the extract, which is not the same as pulling the active ingredient out of it. Second, nearly all of this research comes from one network of institutes, and the people who ran the studies were also the people who made the product. None of the headline results have been reproduced by an unconnected laboratory.

There is no mechanism for epithalamin in the sense that word normally carries, because the substance is not defined. A mechanism requires a molecular entity that binds something; an extract of unknown composition can only have a mechanism attributed to it by inference from its effects. What the literature actually offers is a set of reported downstream effects plus a theoretical frame imported from the synthetic peptides developed later. The best-documented reported effect is on pineal melatonin output. Epithalamin is described as restoring night-time melatonin secretion in ageing humans and rhesus monkeys and as normalizing circadian amplitude (PMIDs 15452611, 17969590), with a commercial successor preparation reported to raise night-time urinary 6-sulfatoxymelatonin 1.9-fold in elderly patients selected for low pineal function (PMID 28849889). Because melatonin is itself a radical scavenger and a circadian signal, a genuine melatonin effect would plausibly carry downstream antioxidant and rhythm consequences, and this is the programme's preferred explanatory chain: the 1998 lifespan paper ends by proposing that the antioxidative properties of epithalamin are what extend lifespan (PMID 9701766). The antioxidant work is more direct. Reported effects include suppressed chemiluminescence and lipid-peroxidation products in rat serum, increased total antioxidant activity and superoxide dismutase activity, and reduced conjugated hydroperoxides and ketodienes in Drosophila tissue with increased catalase and SOD (PMIDs 11335874, 9226628). A 2007 paper argues that the preparation does more than scavenge directly — that it also induces expression of SOD and ceruloplasmin, and may chelate transition metals — and claims this makes it more effective than melatonin in some assays (PMID 17317455). A 2012 hypoxia study likewise reported epithalamin outperforming exogenous melatonin at protecting hippocampal neurons from free-radical damage (PMID 23330089). If true, that argues the extract is doing something melatonin alone does not, which would also mean the melatonin story cannot be the whole explanation. The broader Khavinson frame — that short peptides act as tissue-specific epigenetic regulators binding DNA directly and switching gene expression — was developed for the defined synthetic peptides and is applied to epithalamin by association rather than by evidence specific to the extract. That frame has its own difficulties, chiefly that short peptides are degraded rapidly by aminopeptidases and that no structural characterization of a sequence-specific peptide-DNA complex has been published. For epithalamin the difficulty is more basic still: no proposed mechanism can be tested against a substance whose composition has not been disclosed, and no component of it has been purified and shown to reproduce the extract's effects. Tissue-specific activity in organotypic culture has been reported for the cytomedins as a class (PMID 12096446), but this is an observed pattern, not a mechanism.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Epithalamin:

• 01What is actually in it. No public composition, molecular-weight profile, peptide inventory or reference standard has been released for epithalamin. Until that exists, every other question below is unanswerable in principle, and no two batches can be shown to be the same substance.
• 02Whether any of it replicates outside the programme. Of 73 PubMed-indexed papers mentioning epithalamin in title or abstract, 48 carry Khavinson, Anisimov or Morozov as an author, and most of the rest come from the same two institutes or close collaborators. No headline finding — lifespan, mortality, melatonin restoration — has been reproduced by an unconnected laboratory.
• 03Whether the mortality findings survive blinding. Both the 266-person cohort and the Ukrainian coronary cohort report effect sizes with no parallel in validated geriatric medicine, from unblinded studies run by the institute that supplied the preparation. A placebo-controlled, independently monitored replication of even a fraction of the claimed effect would be the single most informative study anyone could run.
• 04Whether the bidirectional melatonin claim is real or an artefact. The claim that epithalamin raises melatonin when low and lowers it when high is testable — stratify by baseline, pre-register the directional prediction, blind the assessors — and that test has never been performed. As reported, in unblinded studies, it is close to unfalsifiable.
• 05Why the animal lifespan effects were sex- and strain-specific. Male Drosophila showed no effect at all and SHR mice showed no mortality-rate change, which is either a real biological signal worth pursuing or evidence of a fragile result. Nobody has followed it up.
• 06Whether anything in the extract corresponds to Epitalon. The tetrapeptide was synthesized from the extract's amino-acid composition, not purified from it, and no published work demonstrates that AEDG is present in epithalamin as a discrete species or accounts for its activity. This is the empirical question underneath the whole epithalamin-versus-Epitalon confusion, and it is open.
• 07Pharmacokinetics and immunogenicity. Nothing is published on absorption, distribution, half-life or clearance, and nothing on antibody formation against a repeatedly injected bovine tissue extract — an obvious question for a preparation given in courses over years.
• 08Prospective registered trials. There is no registered interventional trial of epithalamin on ClinicalTrials.gov. Every human result discussed on this page was published without prospective registration of its protocol or endpoints.

Forms & Administration

The Russian clinical article is a lyophilized powder in ampoules for reconstitution and intramuscular injection, manufactured in St. Petersburg and described in the literature as a pharmacopoeia preparation. A related commercial polypeptide complex, Pineamin, was studied by the same group in 2017 in work co-authored from the Geropharm group of companies alongside the St. Petersburg institute — a commercial interest worth noting when reading its results. Outside Russia there is no approved formulation and no recognized compounding pathway. Material offered internationally as "epithalamin" cannot be verified against any published specification, since none has been released — a problem that does not arise for a defined synthetic peptide, where a sequence can be confirmed by mass spectrometry.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Epithalamin is not approved by the FDA for any indication, is not a recognized compounding bulk drug substance in the United States, and has never been tested in a registered interventional clinical trial. Nothing on this page is a protocol.

Timeline of Effects

Common Questions

Who Epithalamin Is NOT For

Drug & Supplement Interactions

No formal drug-interaction study of epithalamin has ever been published, and for an extract of undisclosed composition the usual approach — identify the molecule, characterize its metabolism, predict interactions — cannot even be attempted. What the literature supports is a set of theoretical concerns grounded in reported effects rather than documented interactions. The clearest is melatonin. Epithalamin is reported to alter endogenous melatonin output, and reported to do so bidirectionally depending on baseline pineal function (PMID 15452611). Combining it with exogenous melatonin, with melatonin-receptor agonists, or with deliberate light management means stacking an intervention of unpredictable direction on top of one with a known direction. There is a second and stranger wrinkle: two separate papers claim epithalamin outperforms melatonin in antioxidant assays and in protecting hippocampal neurons during hypoxia (PMIDs 17317455, 23330089), which implies activity independent of the melatonin axis and therefore interactions that a melatonin-based model would not predict. Beyond that, the endocrine reports suggest further theoretical concerns. The 1983 human study described bidirectional changes in gonadotropins and prolactin, which would be relevant to anyone on fertility treatment, hormonal contraception or testosterone therapy. A 1998 study in type 2 diabetes reported improved glycaemic compensation and lowered glycated haemoglobin and insulin (PMID 9821374), and the 15-year cardiovascular report described normalized carbohydrate and lipid metabolism — so an additive effect with glucose-lowering medication is plausible on the published evidence, though it has never been tested. None of these are documented interactions. They are places where documented interactions would be expected to exist if anyone looked.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions